CytomX Therapeutics (NASDAQ:CTMX) Receives “Neutral” Rating from HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of CytomX Therapeutics (NASDAQ:CTMX) in a report published on Tuesday morning,Benzinga reports.

CytomX Therapeutics Stock Performance

Shares of CTMX stock opened at $0.98 on Tuesday. CytomX Therapeutics has a fifty-two week low of $0.83 and a fifty-two week high of $5.85. The stock’s fifty day moving average is $1.06 and its two-hundred day moving average is $1.17. The firm has a market capitalization of $76.91 million, a P/E ratio of 5.78 and a beta of 1.03.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.23. The business had revenue of $33.43 million during the quarter, compared to analysts’ expectations of $18.92 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. During the same period in the prior year, the business earned $0.04 earnings per share. On average, equities analysts forecast that CytomX Therapeutics will post -0.05 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CTMX. US Bancorp DE purchased a new position in CytomX Therapeutics during the third quarter worth approximately $40,000. XTX Topco Ltd increased its stake in shares of CytomX Therapeutics by 382.6% in the 2nd quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 48,033 shares during the last quarter. Forefront Analytics LLC increased its stake in shares of CytomX Therapeutics by 206.7% in the 2nd quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 43,176 shares during the last quarter. Cubist Systematic Strategies LLC raised its holdings in shares of CytomX Therapeutics by 96.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 40,309 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of CytomX Therapeutics during the 3rd quarter valued at about $104,000. 67.77% of the stock is currently owned by institutional investors and hedge funds.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.